SpringerLink
Log in

Target Cell Induced T Cell Activation with Bispecific Antibodies: A New Concept for Tumor Immunotherapy

  • Conference paper
Molecular Neuro-oncology and Its Impact on the Clinical Management of Brain Tumors

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 135))

  • 52 Accesses

Abstract

It can hardly be disputed that current treatment of malignant tumors with radiotherapy or cytotoxic drugs fails to produce cure or long-term remission in a large majority of patients, tumors of the nervous system being no exception to this rule.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Waldman TA (1991) Monoclonal antibodies in diagnosis and therapy. Science 252: 1657–1662

    Article  Google Scholar 

  2. Cheung NK (1991) Immunotherapy. Neuroblastoma as a model. Pediatr Clin North Am 38: 425–441

    PubMed  CAS  Google Scholar 

  3. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW 2nd, Longo DL, Gould B, Frankel A, McClay EF, Howell S et al (1991) Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9: 2095–2103

    PubMed  CAS  Google Scholar 

  4. Hwang KM, Fodstad, O, Oldham RK, Morgan AC Jr (1985) Radiolocalization of xenografted human malignant melanoma by a monoclonal antibody (9.2.27) to a melanoma-associated antigen in nude mice. Cancer Res 45: 4150–4155

    PubMed  CAS  Google Scholar 

  5. Dillman RO, Beauregard JC, Sobol RE, Royston I, Bartholomew RM, Hagan PS, Halpem SE (1984) Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells. Cancer Res 44: 2213–2218

    PubMed  CAS  Google Scholar 

  6. Dillman RO (1984) Monoclonal antibodies in the treatment of cancers. Crit Rev Oncol Hematol 1: 357–385

    Article  PubMed  CAS  Google Scholar 

  7. Chatenoud L (1986) The immune response against therapeutic monoclonal antibodies. Immunol Today 7: 367–368

    Article  Google Scholar 

  8. Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293–299

    Article  PubMed  CAS  Google Scholar 

  9. Plückthun A (1992) Mono-and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol Rev 130: 151–188

    Article  PubMed  Google Scholar 

  10. Begent RHJ, Green AJ, Keep PA, Searle F, Jewkes RF, Barratt GM (1982) Liposomally entrapped second antibody improves tumor imaging with radiolabeled (first) antitumor antibody. Lancet ii: 739–742

    Article  Google Scholar 

  11. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling Z, Kidd P, Donnall Thomas E (1987) Monoclonal antibody l F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69: 584–591

    PubMed  CAS  Google Scholar 

  12. Rankin EM, Hekman A, Somers R, ten Bokkel Huinink W (1985) Treatment of two patients with B cell lymphoma with monoclonal anti-idiotype antibodies. Blood 65: 1373–1381

    PubMed  CAS  Google Scholar 

  13. Schroff RW, Woodhouse CS, Foon KA, Oldham RK, Farrell MM, Klein RA, Morgan AC Jr (1985) Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000-dalton melanoma-associated antigen. J Natl Cancer Inst 74: 299–306

    PubMed  CAS  Google Scholar 

  14. Wawrzynczak EJ, Derbyshire EJ (1992) Immunotoxins: the power and the glory. Immunol Today 13: 381–383

    Article  PubMed  CAS  Google Scholar 

  15. Marrack P, Kappler J (1987) The T cell receptor. Science 238: 1073–1079

    Article  PubMed  CAS  Google Scholar 

  16. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, Lindsten T, Thompson CB, June CH (1990) CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75: 1531–1539

    PubMed  CAS  Google Scholar 

  17. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of the CD28 receptor in T-cell activation. Immunol Today 11: 211–216

    Article  PubMed  CAS  Google Scholar 

  18. Linsley PS, Clark EA, Ledbetter JA (1990) The T cell antigen, CD28, mediates adhesion with B cells by interacting with the activation antigen, B7BB 1. Proc Natl Acad Sci USA 87: 5031–5035

    Article  PubMed  CAS  Google Scholar 

  19. Freeman GJ, Freedman AS, Segil JM, Lee G, Whitman JF, Nadler LM (1989) B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 143: 2714–2722

    PubMed  CAS  Google Scholar 

  20. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169: 1042–1049

    Article  PubMed  CAS  Google Scholar 

  21. Schwartz RH (1989) Acquisition of immunological self-tolerance. Cell 57: 1073–1081

    Article  PubMed  CAS  Google Scholar 

  22. Janeway CA Jr (1989) Immunogenicity signals 1,2,3… and 0. Immunol Today 10: 283–286

    Article  PubMed  CAS  Google Scholar 

  23. Staerz UD, Kanagawa O, Bevan MJ (1985) Hybrid antibodies can target sites for attack by T cells. Nature 314: 628–631

    Article  PubMed  CAS  Google Scholar 

  24. Pérez P, Hoffmann,RW, Shaw S, Bluestone JA, Segal DM (1985) Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 316: 354–356

    Google Scholar 

  25. Liu MA, Kranz DM, Kurnick JT, Boyle LA, Levy R, Eisen HN (1985) Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 8648–8652

    Article  PubMed  CAS  Google Scholar 

  26. Jung G, Honsik CJ, Reisfeld RA, Müller-Eberhard HJ (1986) Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates. Proc Natl Acad Sci USA 83: 4479–4483

    Article  PubMed  CAS  Google Scholar 

  27. Jung G, Martin DE, Müller-Eberhard HJ (1987) Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J Immunol 139:639–614

    PubMed  CAS  Google Scholar 

  28. Looney RI, Abraham GN (1984) The Fc portion of intact IgG blocks stimulation of human PBMC by anti-T3. J Immunol 133: 154–156

    PubMed  CAS  Google Scholar 

  29. Landegren U, Andersson J, Wigzell H (1984) Mechanisms of T lymphocyte activation by OKT3 antibodies. A general model for T cell induction. Eur J Immunol 14: 325–328

    Article  PubMed  CAS  Google Scholar 

  30. Quian JH, Titus JA, Andrew SM, Mezzanzanica D, Garrido MA, Wunderlich JR, Segal DM (1991) Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol 146: 3250–3256

    Google Scholar 

  31. Nitta T, Nakata M, Yagita H, Okumura K (1991) Interleukin-2 activated T cells (T-LAK) express CD 16 antigen and are triggered to target cell lysis by bispecific antibody. Immunol Lett 28: 31–37

    Article  PubMed  CAS  Google Scholar 

  32. Lamers CH, van de Griend RJ, Braakman E, Ronteltap CP, Benard J, Stoter G, Gratama JW, Bolhuis RL (1992) Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer 51: 973–979

    Article  PubMed  CAS  Google Scholar 

  33. Jung G, Freimann U, von Marschall Z, Reisfeld RA, Wilmanns W (1991) Target cell-induced T cell activation with bi-and trispecific antibody fragments. Eur J Immunol 21: 2431–2435

    Article  PubMed  CAS  Google Scholar 

  34. Nisonoff A, Rivers MM (1961) Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys 93: 460–466

    Article  PubMed  CAS  Google Scholar 

  35. Hämmerling U, Aoki T, deHarven E, Boyce EA, Okol CJ (1968) Use of hybrid antibody with anti-gamma G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med 128: 1461–1469

    Article  PubMed  Google Scholar 

  36. Raso V, Griffin T (1981) Hybrid antibody with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res 41: 2073–2078

    PubMed  CAS  Google Scholar 

  37. Milstein C, Cuello AC (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537–540

    Article  PubMed  CAS  Google Scholar 

  38. Milstein C, Cuello AC (1984) Hybrid hybridoma and the production of bi-specific monoclonal antibodies. Immunol Today 5: 299–304

    Article  CAS  Google Scholar 

  39. Demanet C, Brissinck J, van Mechelen M, Leo O, Thielemans K (1991) Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3). J Immunol 147: 1091–1097

    PubMed  CAS  Google Scholar 

  40. Brennan M, Davison PF, Paulus H (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin GI fragments. Science 229: 81–83

    Article  PubMed  CAS  Google Scholar 

  41. Weiner G, Hillstrom JR (1991) Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 147: 4035–4044

    PubMed  CAS  Google Scholar 

  42. Garrido MA, Valdayo MJ, Winkler DF, Titus JA, Hecht TT, Perez P, Segal DM, Wunderlich JR (1990) Targeting human T lymphocytes with bispecific antibodies to react against human ovarian carcinoma cells growing in nu/nu mice. Cancer Res 50: 4227–4232

    PubMed  CAS  Google Scholar 

  43. Reid I, Lundy J, Monson J, Nelson H, Ramsay P, Ilstrup D, Donahue JH (1992) Heteroconjugated antibodies enhance lymphocyte-mediated tumor cell lysis in vitro and in vivo. Br J Surg 79: 628–632

    Article  PubMed  CAS  Google Scholar 

  44. Gross J, St. John T, Allison JP (1990) The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J Immunol 144:3201–3210

    PubMed  CAS  Google Scholar 

  45. Townsend SE, Allison JP (1992) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 259: 368–370

    Article  Google Scholar 

  46. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368–376

    Article  PubMed  CAS  Google Scholar 

  47. Mezzanzanica D, Canevari S, Colnaghi MI (1991) Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: from laboratory to clinic. Int J Clin Lab Res 21: 159–164

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Labor für Rationale Immuntherapie, Medizinische Klinik III, Universität München, Klinikum Großhadern, Marchioninistr. 15, 81377, Munich, Germany

    H. Wolf & G. Jung

  2. Institut für Klinische Hämatologie, GSF-Forschungszentrum für Umwelt und Gesundheit, Marchioninistr. 25, 81377, Munich, Germany

    U. Freimann

Authors
  1. H. Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Freimann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Neuropathologie, Universitätskliniken Bonn, Sigmund-Freud-Straße 25, 53105, Bonn, Germany

    O. D. Wiestler

  2. Neurologische Universitätsklinik, Sigmund-Freud-Straße 25, 53105, Bonn, Germany

    U. Schlegel  & J. Schramm  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Wolf, H., Freimann, U., Jung, G. (1994). Target Cell Induced T Cell Activation with Bispecific Antibodies: A New Concept for Tumor Immunotherapy. In: Wiestler, O.D., Schlegel, U., Schramm, J. (eds) Molecular Neuro-oncology and Its Impact on the Clinical Management of Brain Tumors. Recent Results in Cancer Research, vol 135. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85039-4_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85039-4_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85041-7

  • Online ISBN: 978-3-642-85039-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation